Hydrix eyes Indian med-device cos for tech-transfer to develop products in POC diagnostics
Hydrix from Carnegie is now looking at tapping opportunities in technology transfer and joint product development for range of point-of-care (POC) diagnostics with companies in India.The company is a mobile-wireless technology major and an award winner for developing innovative systems covering implantable, insertables, wearables, in-vitro diagnostics, point of care and laboratory test equipment.
Hydrix from Carnegie, a suburb in the State of Victoria, Australia, a leading software and electronic design consultancy, is now looking at tapping opportunities in technology transfer and joint product development for range of point-of-care (POC) diagnostics with companies in India. The company is a mobile-wireless technology major and an award winner for developing innovative systems covering implantable, insertables, wearables, in-vitro diagnostics, point of care and laboratory test equipment.
Currently, India imports 70 per cent of its diagnostics from various countries and the high rate of custom duty has been detrimental to its indigenous manufacturers. Moreover, the country is home to a large diabetic population estimated at 61 million and there is an increasing incidence of life style disorders including hypertension and cardiovascular disease which requires POC diagnostics. The infusion of embedded technology in diagnostics can revolutionize healthcare in India.
“This is where Hydrix, is keen to chip in its expertise so as to help the Indian medical device industry come out with advanced diagnostics that would help its people in the far-flung remote villages to monitor their health parameters,” Peter Lewis, director, business development, Hydrix told Pharmabiz at the sidelines of interaction.
“India’s domination in information technology and large number of cell phone users, vast population and growing incidence of diseases has created a need for quick tests for early treatment protocols. With a decade of experience, we are now assessing the Indian market to understand the medical device industry and patient needs to tap the opportunities,” he added.
Specifically in India, we are looking at point-of-care and laboratory test equipment. There is also a huge opportunity to develop implantables too. Since, there is an impressive base of nine million cell phone subscribers in a country with 1.2 billion population, we could develop a technology that can be linked to the mobile to test and report the information including ECG to the closest hospitals, said Lewis.
The Indian medical technology industry can build its revenues from its domestic market with advanced and easy to use point of care systems. Hydrix can provide the high quality design software known for both functionality and regulatory compliance like FDA-510K, PMA and De Novo, CE and TGA design for production transfer and validation.
Hydrix has also interacted with over 25 companies in India which are a combination of start-ups and established players to look at collaborations or joint ventures. Considerable interest is evinced and we are hoping these discussions would get converted into potential business deals, said Lewis.
The size of the medical devices sector in Australia is estimated at Aus$ 300 million and Indian market for the same is valued at $2.5 billion in 2012.
The global slowdown of 2009 had impacted for a while but from 2012, there has been an increase in investments by 30 per cent. Even the Victorian Government under its Market Validation Programme has provided an Aus$ 20 million grant for three years for medical devices R&D, said Lewis.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.